MiRNA Let-7a and Let-7d Are Induced by Globotriaosylceramide via NF-kB Activation in Fabry Disease.


Journal

Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097

Informations de publication

Date de publication:
30 07 2021
Historique:
received: 22 06 2021
revised: 22 07 2021
accepted: 26 07 2021
entrez: 27 8 2021
pubmed: 28 8 2021
medline: 11 2 2022
Statut: epublish

Résumé

Fabry disease is a hereditary genetic defect resulting in reduced activity of the enzyme α-galactosidase-A and the accumulation of globotriaosylceramide (Gb3) in body fluids and cells. Gb3 accumulation was especially reported for the vascular endothelium in several organs. Three Fabry disease patients were screened using a micro-RNA screen. An in vitro approach in human endothelial cells was used to determine miRNA regulation by Gb3. In a micro-RNA screen of three Fabry patients undergoing enzyme replacement therapy, we found that miRNAs let-7a and let-7d were significantly increased after therapy. We demonstrate in vitro in endothelial cells that Gb3 induced activation of NF-κB and activated downstream targets. In addition, NF-κB activity directly reduced let-7a and let-7d miRNA expression as inhibiting NF-kB nuclear entry abolished the Gb3 effects. We suggest that let-7a and let-7d are potential markers for enzyme activity and inflammation in Fabry disease patients.

Sections du résumé

BACKGROUND
Fabry disease is a hereditary genetic defect resulting in reduced activity of the enzyme α-galactosidase-A and the accumulation of globotriaosylceramide (Gb3) in body fluids and cells. Gb3 accumulation was especially reported for the vascular endothelium in several organs.
METHODS
Three Fabry disease patients were screened using a micro-RNA screen. An in vitro approach in human endothelial cells was used to determine miRNA regulation by Gb3.
RESULTS
In a micro-RNA screen of three Fabry patients undergoing enzyme replacement therapy, we found that miRNAs let-7a and let-7d were significantly increased after therapy. We demonstrate in vitro in endothelial cells that Gb3 induced activation of NF-κB and activated downstream targets. In addition, NF-κB activity directly reduced let-7a and let-7d miRNA expression as inhibiting NF-kB nuclear entry abolished the Gb3 effects.
CONCLUSION
We suggest that let-7a and let-7d are potential markers for enzyme activity and inflammation in Fabry disease patients.

Identifiants

pubmed: 34440358
pii: genes12081184
doi: 10.3390/genes12081184
pmc: PMC8394417
pii:
doi:

Substances chimiques

MicroRNAs 0
NF-kappa B 0
Trihexosylceramides 0
mirnlet7 microRNA, human 0
globotriaosylceramide 71965-57-6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Mol Genet Metab. 2017 Nov;122(3):19-27
pubmed: 28947349
Int J Mol Sci. 2018 Nov 23;19(12):
pubmed: 30477121
Haematologica. 2021 Feb 01;106(2):454-463
pubmed: 31974204
Am J Physiol Cell Physiol. 2020 Dec 1;319(6):C967-C979
pubmed: 32667865
PLoS One. 2017 Feb 2;12(2):e0167969
pubmed: 28151938
Diabetes. 2017 Aug;66(8):2266-2277
pubmed: 28487436
Genet Med. 2009 Nov;11(11):790-6
pubmed: 19745746
Liver Int. 2020 Jul;40(7):1693-1700
pubmed: 32301252
JAMA. 1999 Jan 20;281(3):249-54
pubmed: 9918480
Sci Rep. 2019 Oct 24;9(1):15277
pubmed: 31649303
Biochim Biophys Acta. 2016 Feb;1863(2):360-7
pubmed: 26658719
Biochem Biophys Res Commun. 2019 Nov 19;519(4):740-746
pubmed: 31547989
Obes Surg. 2018 Sep;28(9):2804-2810
pubmed: 29693219
Genet Med. 2016 Dec;18(12):1181-1185
pubmed: 27195818
Biochem Biophys Res Commun. 2016 Jun 3;474(3):447-451
pubmed: 27137842
J Am Soc Nephrol. 2017 May;28(5):1631-1641
pubmed: 27979989
Am J Hum Genet. 2006 Jul;79(1):31-40
pubmed: 16773563
J Thromb Haemost. 2007 Dec;5(12):2520-8
pubmed: 17922812
Mol Genet Metab. 2008 Nov;95(3):163-8
pubmed: 18707907
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001651
pubmed: 20457564
JIMD Rep. 2015;22:1-10
pubmed: 25690728

Auteurs

Nadine Maier (N)

Department of Internal Medicine II/Cardiology, Medical University of Vienna, 1090 Vienna, Austria.

Constantin Gatterer (C)

Department of Internal Medicine II/Cardiology, Medical University of Vienna, 1090 Vienna, Austria.

Patrick Haider (P)

Department of Internal Medicine II/Cardiology, Medical University of Vienna, 1090 Vienna, Austria.

Manuel Salzmann (M)

Department of Internal Medicine II/Cardiology, Medical University of Vienna, 1090 Vienna, Austria.

Christoph Kaun (C)

Department of Internal Medicine II/Cardiology, Medical University of Vienna, 1090 Vienna, Austria.

Walter S Speidl (WS)

Department of Internal Medicine II/Cardiology, Medical University of Vienna, 1090 Vienna, Austria.

Gere Sunder-Plassmann (G)

Department of Internal Medicine III/Nephrology, Medical University of Vienna, 1090 Vienna, Austria.

Bruno K Podesser (BK)

Center for Biomedical Research, Medical University of Vienna, 1090 Vienna, Austria.
Ludwig Boltzmann Institute for Cardiovascular Research, 1090 Vienna, Austria.

Johann Wojta (J)

Department of Internal Medicine II/Cardiology, Medical University of Vienna, 1090 Vienna, Austria.
Ludwig Boltzmann Institute for Cardiovascular Research, 1090 Vienna, Austria.

Senta Graf (S)

Department of Internal Medicine II/Cardiology, Medical University of Vienna, 1090 Vienna, Austria.

Max Lenz (M)

Department of Internal Medicine II/Cardiology, Medical University of Vienna, 1090 Vienna, Austria.

Philipp J Hohensinner (PJ)

Department of Internal Medicine II/Cardiology, Medical University of Vienna, 1090 Vienna, Austria.
Center for Biomedical Research, Medical University of Vienna, 1090 Vienna, Austria.
Ludwig Boltzmann Institute for Cardiovascular Research, 1090 Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH